Zacks Investment Research downgraded shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) from a buy rating to a hold rating in a research report released on Tuesday, November 7th.
According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
Several other brokerages have also commented on KPTI. Royal Bank Of Canada restated a buy rating and set a $14.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, October 18th. Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the company a buy rating in a research note on Thursday, October 12th. Jefferies Group LLC reiterated a buy rating on shares of Karyopharm Therapeutics in a research note on Friday, October 13th. Robert W. Baird reiterated a buy rating on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Finally, ValuEngine downgraded Karyopharm Therapeutics from a hold rating to a sell rating in a report on Thursday, August 31st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and a consensus target price of $17.33.
Karyopharm Therapeutics (NASDAQ:KPTI) opened at $11.47 on Tuesday. Karyopharm Therapeutics has a 12-month low of $7.48 and a 12-month high of $14.63.
Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative return on equity of 76.83% and a negative net margin of 67,267.47%. research analysts predict that Karyopharm Therapeutics will post -2.59 EPS for the current year.
WARNING: This piece was first published by BBNS and is owned by of BBNS. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://baseballnewssource.com/markets/zacks-investment-research-downgrades-karyopharm-therapeutics-inc-kpti-to-hold/1763317.html.
In related news, Director Mansoor Raza Mirza sold 2,882 shares of the firm’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the sale, the director now directly owns 2,882 shares in the company, valued at approximately $31,702. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Christopher Brett Primiano sold 4,958 shares of the firm’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $11.25, for a total value of $55,777.50. The disclosure for this sale can be found here. In the last three months, insiders sold 15,653 shares of company stock worth $174,728. Company insiders own 14.71% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Bank of America Corp DE increased its position in shares of Karyopharm Therapeutics by 0.7% during the 1st quarter. Bank of America Corp DE now owns 46,127 shares of the company’s stock valued at $592,000 after purchasing an additional 308 shares during the period. ProShare Advisors LLC increased its position in shares of Karyopharm Therapeutics by 8.0% during the 2nd quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock valued at $246,000 after purchasing an additional 2,021 shares during the period. American International Group Inc. grew its holdings in shares of Karyopharm Therapeutics by 20.9% in the 1st quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after acquiring an additional 2,836 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Karyopharm Therapeutics by 4.5% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock worth $1,111,000 after acquiring an additional 3,762 shares during the last quarter. Finally, Swiss National Bank grew its holdings in shares of Karyopharm Therapeutics by 10.9% in the 1st quarter. Swiss National Bank now owns 40,850 shares of the company’s stock worth $525,000 after acquiring an additional 4,000 shares during the last quarter. Institutional investors own 59.52% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with our FREE daily email newsletter.